blank
Hundreds of companies around the world are chasing an emerging market for cheaper copies of costly biotech drugs, with more than 700 so-called biosimilars now in development or already approved, according to a major study of the sector.Biotech medicines - made from proteins and other large molecules - account for six of the 10 biggest-selling drugs in the world today, led by AbbVie’s $12 billion-a-year rheumatoid arthritis injection Humira.
